Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Solvay Pharmaceuticals Clear all

Conditions: Prostate Cancer
Interventions: AndroGel, placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Interventions: bifeprunox, Placebo; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 35
States / cities: Phoenix, Arizona • Carson, California • Long Beach, California + 28 more

Conditions: Diabetes Mellitus Type 2
Interventions: androgel, androgel 10g, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 35 Years to 75 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Aging, Obesity, Insulin Resistance, Hypogonadism
Interventions: Topical testosterone gel 10 g/day; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 60 Years to 90 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Bifeprunox; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Healthy Volunteers
Interventions: Testosterone, Goserelin acetate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years to 75 Years · Male only
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: Tedisamil sesquifumarate; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Honolulu, Hawaii • Tullahoma, Tennessee

Conditions: Hypogonadism
Interventions: Testosterone; Drug
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 60 Years to 80 Years · Male only
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Migraine With Aura, Migraine Without Aura
Interventions: Dronabinol MDI; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 29
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more

Conditions: Menopause
Interventions: esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, Esterified estrogens 1.25 mg; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 78
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more

Conditions: Hypogonadism
Interventions: Testosterone gel 1.62%; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Hot Flushes, Menopause, Postmenopause
Interventions: Esterified Estrogens (EE) and Methyltestosterone (MT); Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 1,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 88
States / cities: Montgomery, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 69 more

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: Tedisamil sesquifumarate; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 4
States / cities: Los Angeles, California • Santa Ana, California • Honolulu, Hawaii + 1 more

Conditions: Depression Bipolar
Interventions: Bifeprunox; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 40
States / cities: Birmingham, Alabama • Beverly Hills, California • National City, California + 36 more

Conditions: Menopause
Interventions: esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 78
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Bifeprunox; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: National City, California

Conditions: Hypogonadism, Diabetes
Interventions: Testosterone gel, placebo; Drug
Lead sponsor: Diabetes Center of the Southwest; Other
Eligibility: 35 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Midland, Texas

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: University of Washington; Other
Eligibility: 60 Years to 90 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Pentadecanoic acid (PA) and Triheptadecanoin (THA); Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postmenopausal Symptoms
Interventions: Estrogel, Placebo; Drug · Other
Lead sponsor: ASCEND Therapeutics; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more

Conditions: Early Stage Parkinson Disease
Interventions: Pardaprunox, pramipexole, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more

Conditions: Advanced Stage Parkinson's Disease
Interventions: Pardoprunox; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 14
States / cities: La Jolla, California • San Francisco, California • Fort Lauderdale, Florida + 11 more

Conditions: Hypogonadism, Benign Prostatic Hyperplasia
Interventions: Dutasteride, Testosterone gel, Placebo dutasteride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 50 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase Delayed Release; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 1 Month to 6 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Boise, Idaho • Louisville, Kentucky • Boston, Massachusetts + 8 more

Search by objective public record fields.

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

Does Testosterone Improve Function in Hypogonadal Older Men

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

Study Evaluating Bifeprunox in Bipolar Depression

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes

Hormone and Information Processing Study

Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

TRADE-Testosterone Replacement and Dutasteride Effectiveness

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis